Health & Fitness
PSMA PET Imaging Agent For Prostate Cancer Now at SBUH
The FDA-approved imaging agent visualization of lymph nodes, bone and soft tissue metastasis to determine if cancer is present or absent.
Press release from Stony Brook Medicine:
Aug. 13, 2021
According to the American Cancer Society, an estimated one in eight men will be diagnosed with prostate cancer in their lifetimes. Until now, conventional imaging, especially at low PSA (Prostate-Specific Antigen) levels, has not been able to identify the location and extent of the disease in the majority of cases of men with a suspected cancer recurrence. Now, Stony Brook University Cancer Center, in conjunction with Stony Brook Advanced Imaging, is the first on Long Island to offer men with prostate cancer targeted Positron Emission Tomography (PET) imaging with PYLARIFY® (piflufolastat F 18) Injection, a Prostate-Specific Membrane Antigen (PSMA) imaging agent.
Find out what's happening in Three Villagefor free with the latest updates from Patch.
Backed by the experts and state-of-the-art technology at Stony Brook Advanced Imaging Center, this type of imaging enables visualization of lymph nodes, bone and soft tissue metastasis to determine the presence or absence of recurrent and/or metastatic prostate cancer.
Dr. Dinko Franceschi, Chief of Nuclear Medicine and Director of Clinical PET in the Department of Radiology at the Renaissance School of Medicine, states, “For years, there has not been good imaging modalities for prostate cancer – now we have this tool to see exactly where the tumor is in a patient, which will help in determining the best approach going forward.”
Find out what's happening in Three Villagefor free with the latest updates from Patch.
Developed by Lantheus, PYLARIFY® was recently approved by the U.S. Food and Drug Administration (May 2021) as the first commercially available PSMA PET imaging agent for prostate cancer. Those with suspected metastasis who are candidates for initial definitive therapy or those with suspected recurrence based on elevated serum PSA level are eligible for the scan.
PSMA scans are available at two Stony Brook Medicine imaging centers (Riverhead and Stony Brook) with more locations to follow.
For more information or to make an appointment, visit imaging.stonybrookmedicine.edu. To learn more about Stony Brook Cancer Center and prostate cancer treatment, visit cancer.stonybrookmedicine.edu.
This press release was produced by Stony Brook Medicine. The views expressed here are the author's own.
